ALUMIS INC. (ALMS) Form 8-K — Aug 13, 2026
Alumis reported second quarter 2026 financial results with cash, cash equivalents and marketable securities of $502.3 million, which it expects to fund operations into the fourth quarter of 2027. Net loss was $142.2 million, including a $41.8 million impairment of the lonigutamab acquired IPR&D asset after the company decided to explore strategic alternatives for that program. The clinical highlight was long-term ONWARD3 data showing 75% of patients achieved PASI 90 and 54% achieved complete skin clearance (PASI 100) after up to 48 weeks of envudeucitinib in plaque psoriasis (n=773), which management called the highest reported PASI 100 rate among oral therapies.
Key figures
- Revenue
- 1662000
- Guidance
- Cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.
- Total Assets
- 560618000
- Cash Position
- 502300000
- Onward3 n
- 773
- Ga expense q2 2025
- 34450000
- Ga expense q2 2026
- 23356000
- Rnd expense q2 2025
- 108755000
- Rnd expense q2 2026
- 85337000
- Nda submission target
- Q4 2026
- Onward3 pasi90 rate 48wk
- 75%
- Onward3 pasi100 rate 48wk
- 54%
- Lumus sle topline expected
- Q3 2026
- Impairment loss lonigutamab
- 41824000
- A005 phase2 parkinsons start
- 1H 2027
- Collaboration revenue q2 2025
- 2700000
- Collaboration revenue q2 2026
- 1700000
- Prior year q2 2025 net income
- 59321000
- Prior year acelyrin merger gain
- 187907000
Price after filing
Close on the filing date to close N calendar days later (from $25.37). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.